IRIS UniCatt

Chiloiro, Sabrina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.901
AS - Asia 3.544
EU - Europa 2.386
SA - Sud America 919
AF - Africa 107
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 2
AN - Antartide 1
Totale 10.871
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.728
SG - Singapore 1.566
BR - Brasile 744
CN - Cina 722
VN - Vietnam 558
IT - Italia 506
DE - Germania 445
SE - Svezia 324
FR - Francia 263
GB - Regno Unito 139
FI - Finlandia 129
JP - Giappone 125
RU - Federazione Russa 109
IE - Irlanda 105
ID - Indonesia 104
IN - India 104
PL - Polonia 90
HK - Hong Kong 84
CA - Canada 78
AR - Argentina 69
UA - Ucraina 69
MX - Messico 57
NL - Olanda 48
BD - Bangladesh 47
ZA - Sudafrica 40
AT - Austria 39
TR - Turchia 31
IQ - Iraq 30
EC - Ecuador 26
ES - Italia 25
KR - Corea 25
BE - Belgio 24
VE - Venezuela 22
PK - Pakistan 18
SA - Arabia Saudita 18
AE - Emirati Arabi Uniti 16
CO - Colombia 16
EG - Egitto 15
CL - Cile 14
IR - Iran 14
UZ - Uzbekistan 12
MA - Marocco 11
PE - Perù 11
PY - Paraguay 11
CI - Costa d'Avorio 9
AZ - Azerbaigian 8
HU - Ungheria 8
JO - Giordania 8
KE - Kenya 8
LT - Lituania 8
RO - Romania 8
DO - Repubblica Dominicana 7
MY - Malesia 7
AL - Albania 6
CZ - Repubblica Ceca 6
LK - Sri Lanka 6
PH - Filippine 6
PT - Portogallo 6
RS - Serbia 6
TN - Tunisia 6
JM - Giamaica 5
KZ - Kazakistan 5
AU - Australia 4
CH - Svizzera 4
ET - Etiopia 4
GR - Grecia 4
HN - Honduras 4
IL - Israele 4
MD - Moldavia 4
NZ - Nuova Zelanda 4
OM - Oman 4
PA - Panama 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
AM - Armenia 3
BB - Barbados 3
BG - Bulgaria 3
BS - Bahamas 3
CR - Costa Rica 3
GE - Georgia 3
KG - Kirghizistan 3
NP - Nepal 3
SN - Senegal 3
BH - Bahrain 2
BO - Bolivia 2
DK - Danimarca 2
DZ - Algeria 2
LB - Libano 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
AQ - Antartide 1
BW - Botswana 1
CG - Congo 1
EE - Estonia 1
EU - Europa 1
GA - Gabon 1
GT - Guatemala 1
GU - Guam 1
HR - Croazia 1
Totale 10.852
Salva come PNG Salva come JPEG
Città #
Singapore 858
San Jose 447
Chandler 410
Ashburn 381
Ho Chi Minh City 209
Beijing 160
New York 159
Rome 155
Los Angeles 130
The Dalles 120
Hanoi 113
Lauterbourg 105
Tokyo 103
Hefei 96
Dublin 92
São Paulo 85
Warsaw 81
Jakarta 80
St Louis 79
Ann Arbor 78
Hong Kong 76
Munich 72
Milan 68
Moscow 68
Fairfield 67
Frankfurt am Main 65
Helsinki 58
San Mateo 57
Chicago 56
Dallas 55
Wilmington 52
Boston 49
Council Bluffs 45
Bremen 44
Kent 43
Seattle 41
Cattolica 40
Houston 40
Turku 40
Montreal 39
Marseille 38
Orem 38
Denver 35
Princeton 34
Santa Clara 34
London 32
Da Nang 29
Rio de Janeiro 29
Brooklyn 27
Nanjing 27
Buffalo 24
Jacksonville 24
Nuremberg 24
Brussels 23
Haiphong 22
Seoul 22
Woodbridge 22
Hyderabad 21
Lappeenranta 21
Atlanta 20
Johannesburg 20
North Bergen 20
Cambridge 19
Mexico City 19
Boardman 18
Paris 18
Amsterdam 17
Belo Horizonte 17
Phoenix 17
Stockholm 17
Vienna 16
Chennai 15
Hangzhou 15
Shanghai 15
Guangzhou 14
Hải Dương 14
Poplar 14
Redmond 14
Redwood City 13
Augusta 12
Baghdad 12
Mountain View 12
Mumbai 12
Porto Alegre 12
Querétaro 12
Thái Nguyên 12
Ankara 11
Bexley 11
Dearborn 11
Manchester 11
Norwalk 11
Quito 11
Bari 10
Elk Grove Village 10
Goiânia 10
Lawrence 10
Tashkent 10
Zhengzhou 10
Abidjan 9
Buenos Aires 9
Totale 6.102
Salva come PNG Salva come JPEG
Nome #
Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review 306
Hypophysitis Outcome and Factors Predicting Responsiveness to Glucocorticoid Therapy: A Prospective and Double-Arm Study. 305
Typical and Atypical Pituitary Adenomas: A Single-Center Analysis of Outcome and Prognosis 210
An Overview of Diagnosis of Primary Autoimmune Hypophysitis in a Single Prospective Monocentric Experience 197
Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: An immunohistochemical study 173
Xanthogranuloma of the sellar region: A rare tumor. Case illustration and literature review 159
Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients. 155
Radically resected pituitary adenomas: prognostic role of Ki67 labeling index in monocentric retrospective series and literature review 149
The Changing Clinical Spectrum of Hypophysitis 146
Galectin-3 and Estrogen Receptor Alpha as Prognostic Markers in Prolactinoma: Preliminary Results From a Pilot Study 141
Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response 140
DIAGNOSIS OF ENDOCRINE DISEASE: Primary Empty Sella: a comprehensive review 139
Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study 136
Molecular and Genetic Immune Biomarkers of Primary and Immune-Therapy Induced Hypophysitis: From Laboratories to the Clinical Practice 134
Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. 131
Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second Line Therapies: A Longitudinal Study 131
Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways 126
Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes 126
Pancreas as an Unusual Metastatic Site of Medullary Thyroid Carcinoma: A Case of Very Long-term Follow-up Under Prolonged Treatment with Somatostatin Analogues 122
Pediatric craniopharyngiomas: magnetic resonance imaging assessment for hypothalamus-pituitary axis dysfunction and outcome prediction 122
The changing clinical spectrum of endocrine adverse events in cancer immunotherapy 121
Reappraising the Role of Trans-Sphenoidal Surgery in Prolactin-Secreting Pituitary Tumors. 120
First Case of Mature Teratoma and Yolk Sac Testis Tumor Associated to Inherited MEN-1 Syndrome. 119
Synchronous Bilateral Adrenalectomy in ACTH-dependent Hypercortisolism: Predictors, Biomarkers and Outcomes 116
Autoantibody reactivity profile of primary autoimmune hypophysitis patients: preliminary results 116
Effects of glucocorticoid replacement therapy in patients with pituitary disease: A new perspective for personalized replacement therapy 114
Neuro-radiological features can predict hypopituitarism in primary autoimmune hypophysitis 114
Human leucocyte antigens coeliac haplotypes and primary autoimmune hypophysitis in caucasian patients 112
Empty sella syndrome: Multiple endocrine disorders. 112
The Pathogenic RET Val804Met Variant in Acromegaly: A New Clinical Phenotype? 112
Gut Microbiota, LADA, and Type 1 Diabetes Mellitus: An Evolving Relationship 110
Temporoparietal Fascia Flap (TPFF) in Extended Endoscopic Transnasal Skull Base Surgery: Clinical Experience and Systematic Literature Review 109
SOMATOSTATIN ANALOGUES VS ACTIVE SURVEILLANCE IN SMALL PANCREATIC NEUROENDOCRINE TUMORS 109
Proteomics of Pancreatic Neuroendocrine Tumors: A Systematic Review 108
Genes of the “regulation of lymphocyte activation” pathway may influence immune cells infiltration in growth hormone secreting pituitary tumors 106
Hypothalamitis and pituitary atrophy 106
Unveiling the Etiopathogenic Spectrum of Hypophysitis: A Narrative Review 105
Growth hormone receptor isoforms and fracture risk in adult-onset growth hormone-deficient patients. 105
Pleomorphicskin eruptions in a COVID-19 affected patient: Case report and review of the literature 105
Upfront Oxaliplatin–Fluoropyrimidine Chemotherapy and Somatostatin Analogues in Advanced Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Tumors 104
Cancer screening in patients with acromegaly: a plea for a personalized approach and international registries 104
Pituitary Enlargement and Hypopituitarism in Patients Treated with Immune Checkpoint Inhibitors: Two Sides of the Same Coin? 104
The Role of Growth Hormone Receptor Isoforms and Their Effects in Bone Metabolism and Skeletal Fragility 104
Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant 103
Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review 102
Understanding the effect of acromegaly on the human skeleton. 102
Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours 102
Pregnancy in Autoimmune Hypophysitis: Management of a Rare Condition 101
The Differential Diagnosis between Pseudo Cushing's Syndrome and True Cushing's Syndrome in a Septic Patient in the Pre-Agonal Phase: A Case Report 100
Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. 100
Tumor features in adult papillary and adamantinomatous craniopharyngioma: neuroradiological evaluation of pituitary-hypothalamic-axis dysfunction and outcome prediction 97
Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs. 97
IGF-I levels during standard Lanreotide dose predicts biochemical outcome of high-frequency regimen in acromegaly 96
Topography and Radiological Variables as Ancillary Parameters for Evaluating Tissue Adherence, Hypothalamic-Pituitary Dysfunction, and Recurrence in Craniopharyngioma: An Integrated Multidisciplinary Overview 96
Multidisciplinary management of difficult/aggressive growth-hormone pituitary neuro-endocrine tumors 95
Short- and long-term responsiveness to low dose growth hormone (GH) in adult GH deficiency: Role of GH receptor polymorphism. 95
Trouillas's Grading and Post-Surgical Tumor Residue Assessment in Pituitary Adenomas: The Importance of the Multidisciplinary Approach 93
Clinical management of teratoma, a rare hypothalamic-pituitary neoplasia 93
Multidimensional geriatric evaluation in acromegaly: a comparative cross-sectional study 93
Cytokines and chemokines modulate the growth of pituitary adenoma/neuroendocrine tumors: preliminary results of a monocenter prospective pilot study 92
The multi-biomarker acro-TIME score predicts fg-SRLs response: preliminary results of a retrospective acromegaly cohort 89
Molecular and Genetic Immune Biomarkers of Primary and Immune-Therapy Induced Hypophysitis: From Laboratories to the Clinical Practice 88
Trouillas’s Grading and Post-Surgical Tumor Residue Assessment in Pituitary Adenomas: The Importance of the Multidisciplinary Approach 87
Prevalence of morphometric vertebral fractures in "difficult" patients with acromegaly with different biochemical outcomes after multimodal treatment. 87
The immune microenviroment in somatotropinomas: from biology to personalized and target therapy 85
Acromegaly can be cured by first-line pasireotide treatment? 84
Acromegaly in the elderly patients 84
Second line treatment of acromegaly: Pasireotide or Pegvisomant? 80
Reliability of intraoperative visual evoked potentials (iVEPs) in monitoring visual function during endoscopic transsphenoidal surgery 80
Letter: A Multicenter, Propensity Score- Matched Assessment of Endoscopic Versus Microscopic Approaches in the Management of Pituitary Adenomas 80
Systemic comorbidities of acromegaly in real-life experience: which difference among young and elderly patients? 79
Artificial Intelligence for Individualized Radiological Dialogue: The Impact of RadioBot on Precision-Driven Medical Practices 79
Tumor features in adult papillary and adamantinomatous craniopharyngioma: neuroradiological evaluation of pituitary-hypothalamic-axis dysfunction and outcome prediction 79
GH receptor polymorphisms guide second-line therapies to prevent acromegaly skeletal fragility: preliminary results of a pilot study 78
CD68+ and CD8+ immune cells are associated with the growth pattern of somatotroph tumors and response to first generation somatostatin analogs 78
Empty sella syndrome: an update 78
Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response 78
A Toluene-induced Infundibulo-neuro-hypophysitis: Presentation of a New Cause of Hypophysitis Secondary to Toxic Exposure and Review on Toluene Inhalation Endocrine Effects 76
Consensus on criteria for acromegaly diagnosis and remission 76
Hypophysitis in COVID-19: a systematic review 75
Bone health and skeletal fragility in second- and third-line medical therapies for acromegaly: preliminary results from a pilot single center experience 74
De-escalation treatment with pasireotide for acromegaly: a long-term experience 74
Colon Cancer Presenting as Pituitary Mass and Hypopituitarism: Recognition and Multidisciplinary Approach of a Rare Case 74
Clinical implications of the 2022 WHO classification on the multidisciplinary management of PitNETS patients 72
Factors associated with disease control failure in acromegaly patients treated with pegvisomant: an ACROSTUDY analysis 72
Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study 72
Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences 71
Interpretable Machine Learning-Based Prediction of Intraoperative Cerebrospinal Fluid Leakage in Endoscopic Transsphenoidal Pituitary Surgery: A Pilot Study 69
Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life 69
The clinicopathological PANOMEN-3 classification predicts pituitary adenoma prognosis: a real-world retrospective single center study of a surgically treated cohort 66
The Role of Testosterone in Spermatogenesis: Lessons From Proteome Profiling of Human Spermatozoa in Testosterone Deficiency 65
Predictors of residual and recurrent pituitary neuroendocrine tumors: impact of medial cavernous sinus wall invasion and Trouillas grading 62
Lights or shadows, a promising future for positron emission tomography in pituitary tumors: a systematic review 61
Markers of humoral and cell-mediated immune response in primary autoimmune hypophysitis: a pilot study 61
Cholecalciferol Use Is Associated With a Decreased Risk of Incident Morphometric Vertebral Fractures in Acromegaly 61
Bone safety of dual-release hydrocortisone in patients with hypopituitarism. 60
Cerebrospinal fluid and serum biomarkers in idiopathic intracranial hypertension: A systematic review 59
The paradoxical GH response at OGTT does not predict Pasireotide efficacy but matters for glucose metabolism 59
Vitamin D in pituitary driven osteopathies 56
The curious case of headaches and Rathke’s cleft cysts 53
Totale 10.370
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.852
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.852
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202158 0 0 0 0 0 0 0 0 0 28 28 2
2021/2022474 20 11 6 37 76 25 9 85 23 21 54 107
2022/20231.087 132 153 78 190 56 161 61 78 103 19 27 29
2023/2024658 31 121 23 31 35 113 28 10 39 40 85 102
2024/20251.939 37 42 122 81 91 70 38 54 237 193 449 525
2025/20265.961 773 251 483 994 921 348 989 361 380 461 0 0
Totale 11.073